Graham Capital Management, L.P. Immuno Gen, Inc. Transaction History

Graham Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 22, 2023	BUY	$14.09 - $19.87 $501,209 - $706,815	35,572 New	35,572 $564,000
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $143,539 - $207,298	32,040 New	32,040 $153,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $444,984 - $813,686	-141,265 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $601,788 - $1.06 Million	141,265 New	141,265 $672,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.